Skip to main content

Table 2 Baseline Characteristics

From: Temozolomide and cisplatin in relapsed/refractory acute leukemia

  N = 20
Age 52 (24–73)
Sex 10M/10F
Performance Status 2 (1–3)
Diagnosis:  
   AML 15
   ALL 3
   Biphenotypic 2
Number of prior regimens 3 (1–5)
Prior stem cell transplant 3 (1 auto/2 allo)
Prior AHD 6 (5 MDS/1 aplastic anemia)
Cytogenetics:  
   Good Risk 2 (10%)
   Intermediate Risk 13 (65%)
   High Risk 5 (25%)